Syncom Formulations (India) Limited (524470) Fair Value & Analysis
Healthcare · IN · Market cap ₹976M
Fair value as of: Aug 13, 2026
From 26 valuation models · updated 5 days ago
A solid business, but screening 34% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (₹13.46). The favourable scenario is already priced in.
- The model range is unusually wide (₹4.31 to ₹13.46). The outcome hinges heavily on assumptions, so read the point estimate with caution.
- Solid but not exceptional quality (60/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range ₹3.07 – ₹26.77 · fair‑value band ₹4.31 – ₹13.46 · the ₹15.57 price screens above the ₹10.20 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Syncom Formulations (India) Limited (524470) currently trades at ₹15.57, while our model-based Fair Value estimate is ₹10.20, implying the stock looks roughly 34.5% overvalued today. The Quality Score stands at 60/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Syncom Formulations (India) Limited generated revenue of ₹1.8B at a net margin of 7.9%. Revenue declined 45.7% year over year. The stock trades on a trailing P/E of 10.2 (as of Jul 4, 2026). Fundamentals as of Aug 13, 2026
Our scenario range runs from ₹4.31 (bear case) to ₹13.46 (bull case); at ₹15.57, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 20% below its 52-week high and 52% above its 52-week low. For context, the median of 10 Healthcare peers we cover trades at -38% fair-value upside, at -34%, 524470 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: Growth Earnings (₹15.32) versus Dividend Discount (₹0.4600). Highest evidence: Residual Income (76).
Notify me when 524470 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 60 · Market factors (momentum, volatility) 46
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Syncom Formulations (India) Limited, a pharmaceutical company, discovers, develops, manufactures, and markets a range of healthcare products in India.
Full company description
Syncom Formulations (India) Limited, a pharmaceutical company, discovers, develops, manufactures, and markets a range of healthcare products in India. The company offers approximately 300 pharmaceutical formulations in various dosage forms, such as tablets, capsules, liquids orals, liquid vials and ampoules injections, dry vial injections, dry syrups, ointments, inhalers, and herbals. Its products comprise generics, alpha adrenoceptor agonists, analgesics, antipyretics, anti-inflammatory, anti-ulcer agents, antibiotics, antidepressants, antifungals, antihistamines, antimalarial, antiplatelet agents, antiprotozoal, antivirals, bronchodilators, calcium antagonists, cardiac medicines, central nervous stimulants, cephelo sporins, cortico steroids, estrogen, cough suppressants, erectile dysfunction, and electrolite. The company also offers histamines, homeostatic, hypoglycemic, hypolipidaemics, local anesthetics, multivitamins and nutritional supplements, sedative anticonvulsants, stimulants, and sympathomimetic products, as well as products used in the treatment of gout. In addition, it exports active pharmaceutical ingredients and surgical products; agro and confectionary products comprising rice, wheat flour, chickpeas, soy doc, biscuits, and candies; and fasteners, steel bars, roofing sheets, and jute bags, as well as metal scrap. Additionally, the company rents properties. Syncom Formulations (India) Limited was founded in 1985 and is based in Indore, India.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Syncom Formulations (India) Limited reported revenue of ₹4.7B in FY2025 versus ₹2.4B in FY2021, a compound +17.4%/yr. Reported net income was ₹494M in FY2025, compounding +14.1%/yr from FY2021.
524470 screens 34% overvalued. Compare with AstraZeneca Pharma India Limited →
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Major stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| AstraZeneca Pharma India Limited 506820 | ₹7,754 | ₹810.13 | -90% |
| Granules India Limited 532482 | ₹861.80 | ₹420.24 | -51% |
| FDC Limited 531599 | ₹354.40 | ₹255.06 | -28% |
| Marksans Pharma Limited 524404 | ₹331.65 | ₹151.74 | -54% |
| Bliss GVS Pharma Limited 506197 | ₹524.05 | ₹104.64 | -80% |
| Lincoln Pharmaceuticals Limited 531633 | ₹612.85 | ₹600.51 | -2% |
| Albert David Limited 524075 | ₹808.85 | ₹500.79 | -38% |
| Wanbury Limited 524212 | ₹250.55 | ₹226.69 | -10% |
| Makers Laboratories Limited 506919 | ₹153.20 | ₹105.20 | -31% |
| Syschem (India) Limited 531173 | ₹30.91 | ₹7.53 | -76% |
Compare Syncom Formulations (India) Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Syncom Formulations (India) Limited (524470) overvalued or undervalued?
What is the fair value of 524470?
What is the quality score of 524470?
What is the revenue of Syncom Formulations (India) Limited (524470)?
What is the net profit margin of 524470?
Does Syncom Formulations (India) Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Syncom Formulations (India) Limited and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.